Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

NCT00117598

Last updated date
Study Location
Pfizer Investigational Site
Little Rock, Arkansas, 72205, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Lymphoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Mantle cell lymphoma (MCL) confirmed with histology, immunophenotype, and cyclin D1 analysis

- Received 2 to 7 prior therapies which may include hematopoietic stem cell transplant (i.e. induction + consolidation + maintenance)

- Prior treatment with an alkylating agent and an anthracycline, rituximab, individually or in combination, and status that is at least one of the following:

- Primary disease refractory to at least 2 regimens;

- Refractory to at least 1 regimen after first relapse;

- Refractory or untreated after second or greater relapse;

- Refractory to first line and relapsed after second line. Chemotherapy combinations may include, but are not limited to: CHOP (Cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone), FCM (Fludarabine, cyclophosphamide, mitoxantrone), R-FCM (Rituximab,Fludarabine, cyclophosphamide, mitoxantrone), ICE(Ifosfamide, carboplatin, etoposide), DHAP (Dexamethasone, cisplatin, cytarabine) and hyper-CVAD (Cyclophosphamide, doxorubicin, vincristine, dexamethasone).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects who are less than or equal to six month from allogeneic hematopoietic stem
cell transplant and who are on immunosuppressive therapy or have evidence of graft
versus host disease


- Prior investigational therapy within 3 weeks of first dose. Investigational therapy is
defined as treatment that is not approved for any indication.


- Active central nervous system (CNS) metastases, as indicated by clinical symptoms,
cerebral edema, requirement for corticosteroids and/or progressive growth. (Treated
CNS metastases must be stable for > 2 weeks prior to Day 1.)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

LymphomaStudy Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
NCT00868608
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Loma Linda, California
  5. Loma Linda, California
  6. Loma Linda, California
  7. Mission Hills, California
  8. Mission Hills, California
  9. Chicago, Illinois
  10. Saint Louis Park, Minnesota
  11. Saint Louis, Missouri
  12. Saint Louis, Missouri
  13. Hackensack, New Jersey
  14. Hackensack, New Jersey
  15. Hawthorne, New York
  16. Allentown, Pennsylvania
  17. Carlisle, Pennsylvania
  18. Hershey, Pennsylvania
  19. Lewistown, Pennsylvania
  20. Philadelphia, Pennsylvania
  21. State College, Pennsylvania
  22. Houston, Texas
  23. Gent,
  24. Leuven,
  25. Wilrijk,
  26. Berlin,
  27. Berlin,
  28. Shatin, N.T.,
  29. Debrecen,
  30. Kaposvar,
  31. Kashiwa, Chiba
  32. Chuo-ku, Tokyo
  33. Aichi,
  34. Aichi,
  35. Fukuoka,
  36. Fukuoka,
  37. Kanagawa,
  38. Tokyo,
  39. Seoul, Korea
  40. Rotterdam,
  41. Rotterdam,
  42. Singapore,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
LymphomaStudy Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
NCT00117598
  1. Little Rock, Arkansas
  2. Fountain Valley, California
  3. Los Angeles, California
  4. New Milford, Connecticut
  5. Washington, District of Columbia
  6. Boca Raton, Florida
  7. Honolulu, Hawaii
  8. Chicago, Illinois
  9. Morristown, New Jersey
  10. Buffalo, New York
  11. New York, New York
  12. Rochester, New York
  13. Portland, Oregon
  14. Upland, Pennsylvania
  15. Austin, Texas
  16. Grapevine, Texas
  17. Houston, Texas
  18. Temple, Texas
  19. Seattle, Washington
  20. Buenos Aires,
  21. Buenos Aires,
  22. Cordoba,
  23. East Melbourne, Victoria
  24. Wien,
  25. Brugge,
  26. Gent,
  27. Leuven,
  28. Vila Buarque, Sao Paulo
  29. Porto Alegre - RS,
  30. Edmonton, Alberta
  31. Vancouver, British Columbia
  32. London, Ontario
  33. Ottawa, Ontario
  34. Toronto, Ontario
  35. Greenfield Park, Quebec
  36. Montreal, Quebec
  37. Montreal, Quebec
  38. Providencia, Santiago
  39. Beijing,
  40. Beijing,
  41. Shanghai,
  42. Shanghai,
  43. Shanghai,
  44. Lyon,
  45. Paris Cedex 15,
  46. Paris,
  47. Pierre Benite,
  48. Strasbourg,
  49. Villejuif Cedex,
  50. Ulm, BW
  51. Ulm, BW
  52. Heidelberg,
  53. Mainz,
  54. Bologna,
  55. Catania,
  56. Milano,
  57. Roma,
  58. Rotterdam,
  59. Lublin,
  60. Warszawa,
  61. L'Hospitalet de Llobregat, Barcelona
  62. Pamplona, Navarra
  63. Barcelona,
  64. Madrid,
  65. Madrid,
  66. Lund,
  67. Uppsala,
  68. Aarau,
  69. Plymouth, Devon
  70. Southampton, Hants
  71. Tooting, London
  72. Sutton, Surrey
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
Official Title  ICMJE An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Brief Summary This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Lymphoma
Intervention  ICMJE
  • Drug: Temsirolimus (CCI-779)
    Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
  • Drug: Temsirolimus (CCI-779)
    Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
  • Drug: Investigator's choice

    Any of the following single agent treatments:

    1. Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.
    2. Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days
    3. Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days
    4. Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days
    5. Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,
    6. Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days
    7. Prednisone 40 (20-60) mg/m2 PO daily or every other day
    8. Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day
Study Arms  ICMJE
  • Experimental: A
    Intervention: Drug: Temsirolimus (CCI-779)
  • Experimental: B
    Intervention: Drug: Temsirolimus (CCI-779)
  • Active Comparator: C
    Intervention: Drug: Investigator's choice
Publications * Hess G, Coiffier B, Crump M, Gisselbrecht C, Offner F, Romaguera J, Kang L, Moran PJ. Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis. Exp Hematol Oncol. 2015 Apr 11;4:11. doi: 10.1186/s40164-015-0006-1. eCollection 2015.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 25, 2011)
169
Original Enrollment  ICMJE
 (submitted: June 30, 2005)
177
Actual Study Completion Date  ICMJE January 2011
Actual Primary Completion Date August 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Mantle cell lymphoma (MCL) confirmed with histology, immunophenotype, and cyclin D1 analysis
  • Received 2 to 7 prior therapies which may include hematopoietic stem cell transplant (i.e. induction + consolidation + maintenance)
  • Prior treatment with an alkylating agent and an anthracycline, rituximab, individually or in combination, and status that is at least one of the following:
  • Primary disease refractory to at least 2 regimens;
  • Refractory to at least 1 regimen after first relapse;
  • Refractory or untreated after second or greater relapse;
  • Refractory to first line and relapsed after second line. Chemotherapy combinations may include, but are not limited to: CHOP (Cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone), FCM (Fludarabine, cyclophosphamide, mitoxantrone), R-FCM (Rituximab,Fludarabine, cyclophosphamide, mitoxantrone), ICE(Ifosfamide, carboplatin, etoposide), DHAP (Dexamethasone, cisplatin, cytarabine) and hyper-CVAD (Cyclophosphamide, doxorubicin, vincristine, dexamethasone).

Exclusion Criteria:

  • Subjects who are less than or equal to six month from allogeneic hematopoietic stem cell transplant and who are on immunosuppressive therapy or have evidence of graft versus host disease
  • Prior investigational therapy within 3 weeks of first dose. Investigational therapy is defined as treatment that is not approved for any indication.
  • Active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, requirement for corticosteroids and/or progressive growth. (Treated CNS metastases must be stable for > 2 weeks prior to Day 1.)
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Austria,   Belgium,   Brazil,   Canada,   Chile,   China,   France,   Germany,   Italy,   Netherlands,   Poland,   Spain,   Sweden,   Switzerland,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00117598
Other Study ID Numbers  ICMJE 3066K1-305
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP